BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 26875679)

  • 1. Cheating evolution: engineering gene drives to manipulate the fate of wild populations.
    Champer J; Buchman A; Akbari OS
    Nat Rev Genet; 2016 Mar; 17(3):146-59. PubMed ID: 26875679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetically-modified insects to combat vector-borne diseases — curtain rise or fall?
    Nat Rev Genet; 2016 Mar; 17(3):123. PubMed ID: 27314131
    [No Abstract]   [Full Text] [Related]  

  • 3. Plant genome engineering in full bloom.
    Lozano-Juste J; Cutler SR
    Trends Plant Sci; 2014 May; 19(5):284-7. PubMed ID: 24674878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The promise and peril of CRISPR gene drives: Genetic variation and inbreeding may impede the propagation of gene drives based on the CRISPR genome editing technology.
    Zentner GE; Wade MJ
    Bioessays; 2017 Oct; 39(10):. PubMed ID: 28863233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene targeting technologies in rats: zinc finger nucleases, transcription activator-like effector nucleases, and clustered regularly interspaced short palindromic repeats.
    Mashimo T
    Dev Growth Differ; 2014 Jan; 56(1):46-52. PubMed ID: 24372523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR, the disruptor.
    Ledford H
    Nature; 2015 Jun; 522(7554):20-4. PubMed ID: 26040877
    [No Abstract]   [Full Text] [Related]  

  • 7. The New State of the Art: Cas9 for Gene Activation and Repression.
    La Russa MF; Qi LS
    Mol Cell Biol; 2015 Nov; 35(22):3800-9. PubMed ID: 26370509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR-Cas systems for editing, regulating and targeting genomes.
    Sander JD; Joung JK
    Nat Biotechnol; 2014 Apr; 32(4):347-55. PubMed ID: 24584096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome modification by CRISPR/Cas9.
    Ma Y; Zhang L; Huang X
    FEBS J; 2014 Dec; 281(23):5186-93. PubMed ID: 25315507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN.
    Ul Ain Q; Chung JY; Kim YH
    J Control Release; 2015 May; 205():120-7. PubMed ID: 25553825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacterial CRISPR: accomplishments and prospects.
    Peters JM; Silvis MR; Zhao D; Hawkins JS; Gross CA; Qi LS
    Curr Opin Microbiol; 2015 Oct; 27():121-6. PubMed ID: 26363124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference.
    Barrangou R; Birmingham A; Wiemann S; Beijersbergen RL; Hornung V; Smith Av
    Nucleic Acids Res; 2015 Apr; 43(7):3407-19. PubMed ID: 25800748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering synthetic TALE and CRISPR/Cas9 transcription factors for regulating gene expression.
    Kabadi AM; Gersbach CA
    Methods; 2014 Sep; 69(2):188-97. PubMed ID: 25010559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered CRISPR-Cas9 nucleases with altered PAM specificities.
    Kleinstiver BP; Prew MS; Tsai SQ; Topkar VV; Nguyen NT; Zheng Z; Gonzales AP; Li Z; Peterson RT; Yeh JR; Aryee MJ; Joung JK
    Nature; 2015 Jul; 523(7561):481-5. PubMed ID: 26098369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9 and TALEN-mediated knock-in approaches in zebrafish.
    Auer TO; Del Bene F
    Methods; 2014 Sep; 69(2):142-50. PubMed ID: 24704174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multistage regulator based on tandem promoters and CRISPR/Cas.
    Jia H; Liang T; Wang Z; He Z; Liu Y; Yang L; Zeng Y; Liu S; Tang L; Wang J; Chen Y; Xie Z
    ACS Synth Biol; 2014 Dec; 3(12):1007-10. PubMed ID: 25524111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering the Caenorhabditis elegans genome with CRISPR/Cas9.
    Waaijers S; Boxem M
    Methods; 2014 Aug; 68(3):381-8. PubMed ID: 24685391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methods in Enzymology. The use of CRISPR/Cas9, ZFNs, and TALENs in generating site-specific genome alterations. Preface.
    Doudna JA; Sontheimer EJ
    Methods Enzymol; 2014; 546():xix-xx. PubMed ID: 25398356
    [No Abstract]   [Full Text] [Related]  

  • 19. CRISPR/Cas9 Immune System as a Tool for Genome Engineering.
    Hryhorowicz M; Lipiński D; Zeyland J; Słomski R
    Arch Immunol Ther Exp (Warsz); 2017 Jun; 65(3):233-240. PubMed ID: 27699445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A new method in biotechnology].
    Hofmann-Aßmus M
    MMW Fortschr Med; 2015 Apr; 157(7):75. PubMed ID: 26012467
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 37.